1. Basic Product Identification
Calcitriol
INN Name: Calcitriol
Chemical Identity: 1,25-dihydroxyvitamin D3
Therapeutic Class: Vitamin D analog / calcium regulator
Pharmacological Class: Hormone (active vitamin D metabolite)
Dosage Forms:
Capsules (oral)
Injection (IV)
Topical ointment (psoriasis)
Primary Indications:
Hypocalcemia (especially renal failure)
Secondary hyperparathyroidism (CKD)
Psoriasis (topical)
2. Therapeutic Knowledge
Calcitriol is a hormonal regulator of calcium and phosphorus metabolism.
Clinical uses:
Chronic kidney disease–mineral bone disorder (CKD-MBD)
Hypoparathyroidism
Psoriasis (topical use)
Osteoporosis adjunct (less common)
???? Key benefit:
Direct active form → no activation needed by kidneys
3. Mechanism of Action (MOA)
Calcitriol is the active form of vitamin D3.
It binds to:
Vitamin D Receptor (VDR) → nuclear transcription factor
Effects:
↑ Calcium absorption in intestines
↑ Phosphate absorption
↓ Parathyroid hormone (PTH) synthesis
↑ Osteoblast activity (bone regulation)
???? Net effect:
Restores calcium-phosphate balance
Suppresses secondary hyperparathyroidism
4. Pharmacokinetics (ADME)
Absorption:
Oral: good absorption
Topical: minimal systemic absorption
Distribution:
Binds vitamin D binding protein (DBP)
Metabolism:
Hepatic CYP24A1-mediated degradation
Half-life:
~5–8 hours (short acting)
Excretion:
Bile and feces
⚠️ Narrow therapeutic window → toxicity risk (hypercalcemia)
5. Dosage & Administration
Oral:
0.25 mcg to 1 mcg daily (CKD/hypoparathyroidism)
IV:
Used in dialysis patients for PTH control
Topical (psoriasis):
Applied 1–2 times daily
⚠️ Monitoring required:
Serum calcium
Serum phosphate
PTH levels
6. Formulation Knowledge
Dosage forms:
Soft gelatin capsules (oral)
Sterile injection (IV)
Ointment (0.0003%–0.0006%)
Challenges:
Extremely low dose (microgram level)
Photodegradation sensitive
Fat-soluble compound → lipid-based formulations required
Excipients:
Oil vehicles (MCT oil, olive oil)
Antioxidants (BHT, tocopherol)
Ointment bases (petrolatum)
7. Raw Materials Knowledge
API: Calcitriol (highly potent secocopyright hormone)
Derived from:
Vitamin D3 (cholecalciferol) multi-step activation pathway
Critical raw material concerns:
Photolabile intermediates
Oxidation-sensitive copyright structures
Ultra-low dose handling contamination risk
8. Manufacturing Process Knowledge
API synthesis:
Starting from vitamin D3
Hydroxylation at C1 and C25 positions
Enzymatic or chemical stereoselective synthesis
Purification via HPLC-grade chromatography
Formulation:
Microgram precision blending
Oil-based dissolution systems
Light-protected environment required
Critical controls:
Potency accuracy (µg range)
Uniformity of dosage units
9. Analytical & QC Knowledge
Key QC parameters:
HPLC assay (high sensitivity)
Impurity profiling (CYP degradation products)
Content uniformity (critical)
Dissolution testing (capsules)
Potency testing (bioassay sometimes used)
Photostability testing (ICH Q1B)
Microbial limits (topical forms)
Critical attribute:
Dose accuracy at microgram level
10. Regulatory Knowledge
Approved globally for CKD and hypocalcemia
Listed in WHO essential medicines (vitamin D analogs category)
Requires:
Strict labeling for hypercalcemia risk
Monitoring guidelines (calcium/PTH)
Classified as:
Hormonal drug (not simple supplement)
11. Storage & Stability
Store at 2–8°C or below 25°C (depending on form)
Protect from:
Light (critical)
Heat
Shelf life:
~24 months (capsules)
Shorter for topical forms after opening
Stability risks:
Photodegradation
Oxidation of secocopyright structure
12. Packaging Knowledge
Alu-Alu blister packs (light protection)
Amber glass bottles (capsules)
Sterile ampoules/vials (injectables)
Ointment tubes with UV protection
Secondary packaging:
Light-protective cartons
Clear dosing warnings (hypercalcemia risk)
13. Safety & Toxicology
Major risk:
Hypercalcemia (dose-dependent toxicity)
Symptoms:
Nausea
Weakness
Confusion
Arrhythmia (severe cases)
Other risks:
Hyperphosphatemia
Soft tissue calcification
Contraindications:
Existing hypercalcemia
Vitamin D toxicity
Monitoring:
Serum calcium
Phosphate
Renal function
14. Market & Commercial Knowledge
Competes in:
CKD-MBD therapy market
Vitamin D analog segment
Competitors:
Paricalcitol
Doxercalciferol
Advantages:
Direct active form (fast action)
Limitations:
Narrow safety margin
Market demand:
High in dialysis populations globally
15. Intellectual Property (IP)
Original innovator: Roche (historical development)
Patent status:
Off-patent globally
Generic availability:
High
Innovation areas:
Nano-formulations
Improved topical delivery systems
16. Environmental & EHS Knowledge
Hormonal compound → controlled waste handling
copyright-like environmental persistence concerns
Manufacturing:
Solvent-heavy → require recovery systems
Worker safety:
PPE for microgram handling (potent compound control)
Light-protected production areas
17. Export Documentation Knowledge
Required documents:
COA (API + finished product)
DMF / ASMF
GMP certificate
Stability studies (ICH Q1A/Q1B)
Bioequivalence (oral forms)
Photostability report
MSDS
Batch manufacturing records
18. Business Development Knowledge
Target markets:
Nephrology (dialysis centers)
Dermatology (psoriasis topical)
Endocrinology
Strategy:
Hospital supply chains (CKD patients)
Chronic therapy contracts
Competitive positioning:
“Active vitamin D therapy”
Growth drivers:
Rising CKD prevalence globally
19. Advanced Technical Knowledge
Calcitriol is final active hormone form (no activation needed)
Bypasses kidney activation step → critical in CKD patients
VDR gene transcription affects:
Calcium transport proteins (TRPV6)
PTH suppression pathways
Narrow therapeutic index requires precision Angola dosing systems
20. AI & Digital Knowledge (Modern Pharma)
Applications:
AI-based calcium response prediction models
CKD patient dose optimization algorithms
Photostability prediction using ML
Smart dialysis integration systems
Pharmacovigilance for hypercalcemia risk detection
21. Sales Team Product Knowledge Checklist
Sales must know:
Active vitamin D hormone (not supplement)
Used in CKD and hypocalcemia
Narrow safety margin (hypercalcemia risk)
Requires lab monitoring (Ca, PTH)
Not interchangeable with cholecalciferol
Low-dose microgram precision drug
Strong nephrology hospital demand
22. Most Important Technical Documents
DMF / ASMF
COA (µg-level assay validation)
Stability reports (ICH Q1A/Q1B)
Photostability study
Bioequivalence report (oral forms)
Clinical safety profile (hypercalcemia risk)
Manufacturing validation batch records
Impurity profiling report
23. Ultimate Pharma Product Mastery Summary
Calcitriol is:
The biologically active form of vitamin D3
A critical hormone regulator of calcium-phosphate metabolism
Essential in CKD and hypocalcemia management
A high-potency, narrow therapeutic index drug requiring precision dosing
???? Strategic importance:
Core nephrology drug worldwide
High-demand chronic therapy in dialysis population
Sensitive formulation requiring high technical manufacturing control